



INUSphere® Zentrum
Alpstein Clinic
Appenzell-Switzerland



Swiss Excellence

Therapeutic INUSphere®



ALPSTEINCLINIC

GAIS / SWITZERLAND


Environmental medicine in times of permanent toxic loading and performance requirements

A useful component of modern etiological medicine

Humans these days are exposed to all kinds of toxic loads that get into the body through food and groundwater (pesticides), air pollution (heavy metals), and even medical treatments (ingredients). Depending on their genetic makeup, some people are better than others at eliminating these toxins, which accumulate over a lifetime.

Though many official authorities do not consider this matter a top priority, our analyses regularly show high levels of toxic loading.

It is with good reason that these “external noxae” are labeled as such, for they impede or harm a number of important functional systems in living beings. Depending on the amount and type ingested over shorter or longer periods of time, they can end up damaging human biological organ systems, encouraging or even causing disease.



Unfortunately, it is not that easy for the body to get rid of these toxins, as they tend to bind to cells and organs. The field of alternative medicine offers countless variants and tests for eliminating this “toxic load” from the body, though the toxins’ chemical binding properties mean they are often impossible to properly eliminate solely with gentle methods. These gentle methods only work once the bulk of the toxic load has been removed from the body and the body’s own systems, which had previously been blocked by the toxins, are able to function again.




INUSphere® – more than a medical detox

Highly innovative blood-plasma purification to boost immunity and self-healing powers in cases of chronic and acute metabolic and immune disorders

Large quantities of toxins can be removed from the body very effectively by purifying blood plasma, and even more so by preceding this with a treatment involving toxin-binding substances known as chelates. A special “blood-plasma filtration process” known as INUSphere® has been developed to swiftly and effectively eliminate toxins on a large scale. As a certified INUS partner in Switzerland, the Alpstein Clinic offers this procedure, and, through its close cooperation with the INUS Center in Cham (Germany), also has access to a wealth of global experience in apheresis therapy – resulting in benefits for INUSphere® treatments:

- ✓ Elimination of disease-fostering substances and environmental toxins from the blood
- ✓ Preservation of fundamental proteins, electrolytes, and antibodies
- ✓ Gentle and low risk of side effects
- ✓ May be performed as a day procedure, approx. 2 hours
- ✓ May be integrated into holistic medicine





The therapeutic INUSphere® concept

Apheresis (hemodialysis) as an effective, clinically proven therapy option and disease-prevention treatment

State-of-the-art smart filter systems guarantee a gentle “effective detox” that is still also tailored to individual patient needs. The procedure’s advantage lies in the fact that it eliminates not only toxins ingested from external sources, but also allergens, metabolic waste, inflammatory messengers, infection toxins, and harmful proteins. Originally called Chemopherese® and now further developed and patented as INUSphere®, apheresis is an innovative part of the INUS concept. Based on 6000 years of experience gained by phlebotomy therapists from all the world’s cultures, this modern-day treatment is a special form of high-tech plasma purification and immunomodulation for chronic and acute metabolic and immune disorders (autoimmune diseases).

The original Chemopherese® concept particularly revolved around eliminating toxins, i.e. chemicals such as pesticides and organic solvents, as well as heavy metals. INUSphere® then enhanced this by also removing pathological proteins and immune complexes, metabolic waste, infection toxins, allergens, and inflammatory messengers.



Blood-plasma purification, also known as plasmapheresis (from the Greek *apherein* = to separate), helps the body eliminate harmful proteins and metabolic products (e.g. cholesterol, etc.) or other toxic loads (paraproteins, circulating immune complexes, complex infection toxins, pathoproteins, haptens) and restore dysregulated metabolisms and inflammatory cascades/ the immune system to their natural equilibrium (metabolic/immunomodulation), re-activating the body’s self-healing powers.


Chemopherese® in international medicine

Chemopherese® is not a treatment specific to Swiss or German medicine, but was rather developed by INUS in Bavaria. The system is based on the blood-purification process, which has been tried and tested over the last thirty years. There are currently seventeen national apheresis societies, as well as three international societies: the World Apheresis Association (WAA), the International Society for Apheresis (ISFA), and the European Society for Hemapheresis.

INUSphere® at the Alpstein Clinic

As an INUSphere® Center, the Alpstein Clinic has both a national and international focus. In its international activities, it thus reserves the right to also consult the guidelines and recommendations issued by other international apheresis societies (e.g. the Japanese Society for Apheresis, the American Society for Apheresis, the World Apheresis Association, the International Society for Therapeutic Apheresis, guidelines published by the US Food and Drug Administration etc.) when issuing indications or answering questions relating to apheresis treatment.

How INUSphere® works at the Alpstein Clinic



Graphic: Alpstein Clinic, own diagram



The INUSphere® process

The Alpstein Clinic uses the patented INUSphere® toxin-removal process that is tailored to individual patient needs. There are three different types of filters, whose efficacy has been proven in clinical studies. The process is considered very effective with a high degree of tolerance.

Important: The INUSphere® process performed at our clinic is NOT a PLASMA EXCHANGE, and thus does not have any of the side effects produced by that procedure. Only pathogenic loads – not electrolytes or other healthy components – are filtered out.

ANALYSIS

The process used at the Alpstein Clinic involves conducting chemical and biochemical analyses on the filtered-out waste to measure the amount of eliminated toxins and residual plasma. The analysis results are stored and serve to monitor the treatment process, as well as identify disease history and further plan a holistic treatment program.

TAKING AND RESTORING BLOOD

Blood is taken and restored via the arm veins using special cannulas. Treatment takes approx. two hours, and is performed by the Alpstein Clinic's specially trained and qualified medical staff and assistants.

INDICATIONS AND MONITORING

As an anesthesiology and emergency-medicine specialist trained in therapeutic apheresis, Frank Oberle is responsible for indications and monitoring at our clinic. Quality assurance for the treatment is governed by INUS' quality management system (compliant with ISO 9001-2008). The procedure involves you lying in an electrically adjustable treatment bed, though you do not have to disrobe completely. It lasts approx. two hours and takes place in a pleasant, relaxed setting, with technical monitoring and staff attendance guaranteed at all times.

Frequently asked questions



WHAT EXACTLY CAN BE ELIMINATED FROM THE BODY?

INUSphere® filters out molecules that are often missed by normal detoxes. As such, it is able to remove pathologically modified, toxically loaded (with heavy metals, pesticides, solvents) protein particles from the blood. It also eliminates immune complexes and autoimmune complexes that have been agglutinated (“consumed”) by antigen-antibody reactions, as well as messengers and bacterial debris resulting from inflammations, infections, and chronic pain. Some of the filtered-out substances can then be analyzed.

HOW DOES INUSPHERESE® DIRECTLY IMPACT PHYSICAL HEALTH?

The health-promoting effect extends well beyond the mere substances removed. It takes pressure off the immune system by optimizing microcirculation to improve the oxygen and nutrient supply in the organs and peripheral tissue, and often also to improve pain by removing inflammatory messengers.

HOW DOES INUSPHERESE® DIFFER FROM OTHER PROCEDURES?

The patented INUSphere® is distinguished by its highly complex efficacy, which is achieved by using specific, top-quality differential filters. Other procedures with non-patented names such as “Toxinapheresis,” “Detoxapheresis,” or similar are not established apheresis techniques, and are usually “lipidapheresis” processes involving simple filters, meaning they only remove lipid particles, some of which have substances stuck to them.



Evidence-based indications

Suitable for sensitive patients with acute, chronic, and unclear diseases

The indications for INUSphere® must be seen as (last-resort) treatment attempts within the INUS treatment program when no other conventional or alternative medical options are suitable/known and/or these involve severe, unjustifiable side effects from conventional treatment strategies (see pharmacotherapy, chemotherapy).

Through a special derivation method, the INUSphere® process employed at the Alpstein Clinic enables highly concentrated plasma to be obtained for diagnostic purposes. This plasma can help explain the history and background of the disease, and ultimately ensure this can be used to create a holistic pathogenetic treatment program. The data produced is collected and analyzed in an anonymized database, and published internationally, thus constituting a very important component of evidence-based medicine.

GREATER PROSPECTS FOR TREATMENT OPTIONS

Special new filters make it possible to catch tumor cells or viruses circulating in the blood, and filter them out. This will provide another treatment option not only for patients with environmental toxicity, but also cancer patients and patients suffering from diseases such as severe hepatitis. At the Alpstein Clinic, we firmly believe this method is yet another step in the right direction for our patients, whose health is our utmost priority. We look forward to providing you with detailed information and explanations on the INUSphere® procedure, and outlining its effects and positive aspects.

Internationally recognized indications for the INUSphere® treatment

- **Alzheimer's disease**
- **Toxicity from heavy metals, solvents, and other environmental toxins** causing clinical symptoms of autoimmune diseases and/or nervous diseases and/or skin diseases (e.g. fibromyalgia, blistering skin diseases, toxic nerve damage, kidney damage, MCS, CFS, ciguatera poisoning)
- **Lyme disease as severely progressing late-stage Lyme disease**, which can no longer be controlled conservatively (CFS/ Guillain-Barre syndrome resistant to immunoglobulin therapy/severe treatment-resistant autoimmune diseases, such as rheumatism, systemic collagenoses, lupus diseases, cardiomyopathies based on proven autoantibodies affecting the heart in the case of Lyme disease)
- **Chronic fatigue syndrome (CFS)**
- **Chronic hepatitis C** (covered by national medical insurance category 1 in Japan)
- **EPH gestosis** (EPH = edema-proteinuria-hypertension), Clinical symptoms during pregnancy, triggered by specific antibodies targeting the placenta's blood vessels and the mother's vascular system
- **Fibromyalgia syndrome**
- **Hypertension (high blood pressure)** Positive detection of arterial alpha 1 and/or angiotensin 1 antibodies, impossible or very difficult to treat with conventional pharmacotherapy
- **Multiple sclerosis** (based on studies conducted by the Canadian and American Society for Apheresis)
- **Multiple chemical sensitivity syndrome (MCS)**
- **Hyperbilirubinemia** in congenital metabolic disorders of the liver, with risk of brain damage

LIST OF INDICATIONS FOR THERAPEUTIC APHERESIS AS PER THE INUS CONCEPT:

- Acute hearing loss
- Age-related dry macular degeneration
- Hemophilia with positive detection of factor-V antibodies
- Antiphospholipid syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP)
- Arndt-Gottron scleromyxedema, with glomerulonephritis and positive detection of paraprotein, failure and/or severe side effects of chemotherapy
- Behcet's disease, failure and/or severe side effects of chemo-therapy
- Cardiac allograft vasculopathy
- Colitis ulcerosa, chemotherapy failure and/or risk of surgical removal of intestines
- Cryoglobulinemic vasculitis (autoimmune inflammation of the vascular system caused by cold proteins)
- Dermatomyositis, failure and/or severe side effects of chemotherapy
- Diabetic foot syndrome with risk of limb amputation if conservative, conventional surgical treatment fails
- Dilated cardiomyopathy, positive detection of beta-receptor antibodies
- Dry macular degeneration (adults)
- Encephalitis disseminata (multiple sclerosis), failure of interleukin-alpha treatment/progressive build-up of antibodies to therapeutic interleukin
- Erdheim-Chester disease (with positive detection of paraproteins)

- Failure and/or severe side effects of chemotherapy
- Focal segmental glomerulo-sclerosis of one's own kidneys or following a kidney transplant, with nephro-tic syndrome and/or severe
- hypertriglyceridemia with failure of chemotherapy/cholesterol-synthesis-inhibitor treatment and rapid kidney (loss of kidney function)
- Glomerulonephritis (inflammatory kidney disease) pathogenetic, failure and/or severe side effects of chemotherapy
- Granulomatosis with polyangiitis, with glomerulonephritis and/or failure of chemotherapy (MEPEX study)
- Guillain-Barre syndrome, chronic/ acute
- Hemophilia with positive detection of factor-V antibodies
- Herpes gestationis
- Heterozygous familial hypercholesterolemia with failure/ side effects of conservative treatment and/or premature and progressive arteriosclerosis/heart attack/stroke/ nephrosclerosis
- Homozygous familial hypercholesterolemia
- Hypertriglyceridemia (severe) with pancreatitis
- Hyperviscosity syndrome with plasmocytoma (multiple myeloma) and Waldenström's disease
- IgM-associated polyneuropathy (tumor-associated nervous disorder)
- Inhibitor hemophilia (increased bleeding risk) with positive detection of factor-V antibodies
- Isolated familial Ip(a) hyperlipidemia with premature arteriosclerosis/ heart attack/stroke/nephrosclerosis /

- inoperable arterial occlusive disease of the legs
- Lambert-Eaton syndrome (tumor-associated nervous disorder)
- LA sensitivity (heightened) in cases of kidney transplants
- Linear IgA dermatosis
- Lupus erythematosus with failure/ severe side effects of chemotherapy
- Lupus erythematosus with progressive glomerulonephritis
- Miller-Fisher syndrome (tumor-associated nervous disorder)
- Multiple sclerosis (see also Encephalitis disseminata)
- Necrobiotic xanthogranuloma (with paraprotein)
- Nephrotic syndrome with inflammatory kidney diseases (glomerulonephritis), pathogenetic
- Pemphigus foliaceus, failure and/ or severe side effects of chemotherapy
- Pemphigus vulgaris, failure and/ or severe side effects of chemotherapy
- Peripheral artery occlusive disease (pathogenetic) with failure of conservative and con-ventional surgical treatment options and risk of losing limbs
- Plasmocytoma with hyperviscosity syndrome/ glomerulonephritis
- Polymyositis failure and/or severe side effects of chemotherapy
- Psoriasis (extremely severe bouts with severe psoriatic arthritis), failure and/or severe side effects of chemotherapy
- Raynaud's disease, failure of conservative treatments
- Refsum's disease (accumulation disease)
- Retinitis pigmentosa with Refsum's

- disease
- Rheumatoid arthritis, highly progressive, with failure of chemotherapy
- Scleroderma, progressive and systemic, with glomerulonephritis
- Sjögren's syndrome, failure and/ or severe side effects of chemotherapy
- Stiff-person syndrome
- Waldenström's disease, benign IgM gammopathy with hyperviscosity
- Xanthogranulomatous inflammation (necrobiotic) with paraprotein

CONTRAINDICATIONS:

1. Patients with acute heart disease, or who have recently suffered a heart attack or stroke
2. Patients with severe circulatory complaints or extreme hypotension
3. Multimorbid patients with poor general health (e.g. insufficiently regulated high blood pressure, untreated diabetes, extreme old age, cachexia)
4. Patients with severe coagulatory dysfunction or clear thrombocytopenia (if taking anticoagulants, a moderate version of the procedure may be performed following appropriate preparation and treatment monitoring)
5. Patients in final stages of cancer
6. Acute inflammations and fever
7. Organ failure, such as severe kidney failure
8. Patients with psychoses, panic attacks or anxiety neuroses in relation to needles, blood etc.



Expertise with long-time experience and vision

Families from over 40 countries place their trust in our specialist skills and expertise



Dr. med. Ralf Oettmeier
Head Physician and Chief Medical Director

Orthopedics and osteology, specialized pain therapy, chronic infections, and environmental medicine



Med. pract. Frank Oberle
Head Physician

Functional medicine, head of the INUSphere® Center, anesthesia, emergency medicine



Med. pract. Birgit Kohl, MSc
Head Physician

Pediatric medicine, autoimmune disorders, endocrinology, and biological esthetics



Dr. med. Dr. med. dent. Josef Vizkelety, MSc
Head Dentist and Chief Director of Dentistry

Minimally invasive conservative and prosthetic, metal-free dentistry, maxiofacial surgery and implantology, integrative biological & interdisciplinary medicine/ dentistry, bite rehabilitation



ALPSTEIN CLINIC

Health Center for Integrative Biological Medicine and Dentistry

MEDICAL CONTACT:

Dorfplatz 5
CH-9056 Gais/Switzerland
Tel: +41 71 791 81 00
info@alpstein-clinic.ch
www.alpstein-clinic.ch

LOCATION AND DIRECTIONS:



PATIENTS FROM OVER 40 COUNTRIES:

